We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

134 hedge funds and large institutions have $315M invested in CytomX Therapeutics in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 15

24% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 38

15% more funds holding

Funds holding: 117 → 134 (+17)

5% more capital invested

Capital invested by funds: $298M → $315M (+$16.4M)

3.05% less ownership

Funds ownership: 85.28% → 82.23% (-3.1%)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $5K

Holders
134
Holders Change
+17
Holders Change %
+14.53%
% of All Funds
2.75%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
32
Increased
47
Reduced
38
Closed
15
Calls
–
Puts
$5K
Net Calls
-$5K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$12.2M
2
State Street
State Street
Massachusetts
+$11.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.59M
4
RI
RTW Investments
New York
+$4.16M
5
HIM
Hillsdale Investment Management
Ontario, Canada
+$3.47M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$30.3M
2
BI
BVF Inc
California
-$7.49M
3
MB
MPM BioImpact
Massachusetts
-$6.56M
4
PA
Perceptive Advisors
New York
-$6.29M
5
CS
Candriam SCA
Luxembourg
-$6.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
26
Acadian Asset Management
Massachusetts
$2.46M +$221K +23,816 +9%
Goldman Sachs
27
Goldman Sachs
New York
$2.31M +$1.3M +139,797 +101%
Assenagon Asset Management
28
Assenagon Asset Management
Luxembourg
$2.11M +$2.36M +253,700 New
PPA
29
Parametric Portfolio Associates
Washington
$2.1M +$2.34M +251,475 New
Prudential Financial
30
Prudential Financial
New Jersey
$2.05M -$899K -96,842 -28%
Two Sigma Investments
31
Two Sigma Investments
New York
$2.01M +$578K +62,192 +35%
Massachusetts Financial Services
32
Massachusetts Financial Services
Massachusetts
$1.7M -$48.2K -5,190 -2%
Man Group
33
Man Group
United Kingdom
$1.62M -$724K -77,998 -29%
AQR Capital Management
34
AQR Capital Management
Connecticut
$1.58M +$464K +49,986 +36%
AG
35
Artal Group
Luxembourg
$1.57M +$1.75M +188,000 New
CS
36
Credit Suisse
Switzerland
$1.56M +$625K +67,335 +56%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.51M -$131K -14,147 -7%
Grantham, Mayo, Van Otterloo & Co (GMO)
38
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$1.26M +$1.23M +132,500 +697%
FCM
39
Farallon Capital Management
California
$1.24M +$1.38M +148,952 New
PAG
40
Private Advisor Group
New Jersey
$1.11M -$74.3K -8,000 -6%
MAM
41
Martingale Asset Management
Massachusetts
$1.1M +$1.23M +132,616 New
TI
42
Trexquant Investment
Connecticut
$1.07M +$1.02M +109,863 +597%
Squarepoint
43
Squarepoint
New York
$963K +$961K +103,473 +849%
PP
44
PDT Partners
New York
$937K +$314K +33,819 +43%
Millennium Management
45
Millennium Management
New York
$883K -$1.75M -188,291 -64%
Russell Investments Group
46
Russell Investments Group
United Kingdom
$857K +$85.5K +9,202 +10%
Wells Fargo
47
Wells Fargo
California
$838K +$685K +73,726 +274%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$833K +$76.3K +8,212 +9%
JP Morgan Chase
49
JP Morgan Chase
New York
$828K -$710K -76,433 -43%
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$801K +$534K +57,500 +149%
1
2
3 4 5

CTMX Hedge Fund Activity: Q2 2020 in Review

134 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2020, worth a combined $315M — up 5.5% from $298M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CTMX positions and 15 closed out — a net gain of 17 holders — while 47 added to existing stakes and 38 trimmed.

The largest buyer was Great Point Partners, adding an estimated $12.2M. The largest seller was Victory Capital Management, cutting an estimated $30.3M.

  • 134 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2020, up from 117 in Q1 2020.
  • Funds reported $315M of CytomX Therapeutics stock for Q2 2020, up 5.5% quarter-over-quarter.
  • 32 funds opened new CytomX Therapeutics positions in Q2 2020 and 15 closed out, a net change of +17 holders.
  • The largest CytomX Therapeutics buyer in Q2 2020 was Great Point Partners, an estimated $12.2M added.
  • The largest CytomX Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q2 2020.